Literature DB >> 8724031

Control of hepatic carbohydrate metabolism and haemodynamics in perfused rat liver by arterial and portal angiotensin II.

F Reisenleiter1, N Katz, A Gardemann.   

Abstract

DESIGN: Angiotensin II (AII; 0.2, 5 and 25 nM) was infused during a single-pass perfusion of a rat liver via both the hepatic artery and the portal vein (portal or arterial AII). Infusion occurred both in the absence and in the presence of the AT1-receptor-antagonist losartan (1 and 10 microM). METABOLISM: Arterial and portal AII increased glucose output and shifted lactate uptake to release. Portal AII was 3 (0.2 nM) and 1.5 times (5 and 25 nM) more effective in increasing hepatic glucose release than similar levels of arterial AII. However, 0.2, 5 and 25 nM of arterially and portally applied AII had a similar level of efficiency in switching lactate uptake to release. The metabolic alterations by arterial and portal AII were, however, strongly inhibited by the addition of 1 microM losartan (an AT1-receptor-antagonist) and completely blocked by the presence of 10 microM losartan. HAEMODYNAMICS: Arterial and portal AII decreased the flow in the ipsilateral vessels to a similar extent, both demonstrating similar kinetics. Medium and high levels of arterial and portal AII caused pronounced flow alterations of the contralateral vessels. The AII-dependent reductions of arterial and portal flow were strongly inhibited by the presence of 1 microM losartan and were stopped by 10 microM of this blocker.
RESULTS: The results demonstrate that arterial and portal AII caused alterations in the hepatic metabolism, demonstrating either clear (glucose balance) or no (lactate balance) differences, produced similar reductions of the ipsilateral flow, and pronounced and complex modulations of the contralateral flow.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8724031     DOI: 10.1097/00042737-199603000-00017

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  4 in total

1.  In vivo investigation of estrogen regulation of adrenal and renal angiotensin (AT1) receptor expression by PET.

Authors:  Taofeek K Owonikoko; Maria E Fabucci; Philip R Brown; Nighat Nisar; John Hilton; William B Mathews; Hayden T Ravert; Paige Rauseo; Kathryn Sandberg; Robert F Dannals; Zsolt Szabo
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

2.  Chronic AT1 blockade improves hyperglycemia by decreasing adipocyte inflammation and decreasing hepatic PCK1 and G6PC1 expression in obese rats.

Authors:  Ruben Rodriguez; Andrew Y Lee; Jose A Godoy-Lugo; Bridget Martinez; Hiroyuki Ohsaki; Daisuke Nakano; David G Parkes; Akira Nishiyama; José Pablo Vázquez-Medina; Rudy M Ortiz
Journal:  Am J Physiol Endocrinol Metab       Date:  2021-10-18       Impact factor: 4.310

3.  Angiotensin II or epinephrine hemodynamic and metabolic responses in the liver of L-NAME induced hypertension and spontaneous hypertensive rats.

Authors:  Debora Conte Kimura; Marcia Regina Nagaoka; Durval Rosa Borges; Maria Kouyoumdjian
Journal:  World J Hepatol       Date:  2017-06-18

4.  Mitochondrial uncoupling proteins regulate angiotensin-converting enzyme expression: crosstalk between cellular and endocrine metabolic regulators suggested by RNA interference and genetic studies.

Authors:  Sukhbir S Dhamrait; Cecilia Maubaret; Ulrik Pedersen-Bjergaard; David J Brull; Peter Gohlke; John R Payne; Michael World; Birger Thorsteinsson; Steve E Humphries; Hugh E Montgomery
Journal:  Inside Cell       Date:  2015-08-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.